MAZENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Maze Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$29.70+2.17 (+7.88%)
Close on Oct 19, 2026
- Market cap
- $1.75B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$1.89 (+6.80%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $1.75B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 3.87
- Dividend yield
- –
- Free cash flow yield
- -6.10%
Fundamentals
- Net income
- -$133.59M
- EPS, diluted
- -$2.52
- Free cash flow
- -$106.84M
- Book value per share
- $7.68
- Diluted shares
- 59M
Three years at a glance
Fiscal years 2023 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$145.61M
Net income
-$133.59M
EPS, diluted
-$2.52
Free cash flow
-$106.84M
Reported periodTrailing twelve months